The estimated Net Worth of Harpreet S. Dhaliwal is at least $2.48 Million dollars as of 28 December 2022. Harpreet Dhaliwal owns over 3,990 units of Vaxcyte stock worth over $2,476,298 and over the last 3 years Harpreet sold PCVX stock worth over $0.
Harpreet has made over 1 trades of the Vaxcyte stock since 2022, according to the Form 4 filled with the SEC. Most recently Harpreet exercised 3,990 units of PCVX stock worth $99,989 on 28 December 2022.
The largest trade Harpreet's ever made was exercising 3,990 units of Vaxcyte stock on 28 December 2022 worth over $99,989. On average, Harpreet trades about 798 units every 0 days since 2021. As of 28 December 2022 Harpreet still owns at least 21,808 units of Vaxcyte stock.
You can see the complete history of Harpreet Dhaliwal stock trades at the bottom of the page.
Harpreet's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070.
Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... und Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte executives and other stock owners filed with the SEC include: